Key Financials (Q2 and H1 2025):
- Total revenue: NOK 28.9 million, up 5% from NOK 27.5 million in Q2 2024. H1 2025 total revenues are at NOK 53.8 million, down 7% from NOK 57.6 million in H1 2024.
- Sales revenue: NOK 26.8 million, up 1%, compared to NOK 26.5 million in the same quarter last year. H1 2025 sales are at NOK 50.0 million, down 13% from NOK 56.5 million in H1 2024.
- Revenue mix: Biomanufacturing contributed 68% (NOK 18.1 million); Molecular Tools 32% (NOK 8.8 million) in Q2 2025
- EBITDA: Up 50% to NOK 3.9 million (Q2 2024: NOK 2.6 million). H1 2025 EBITDA at NOK 0.1 (H1 2024: NOK 4.9 million).
Business Segment highlights
- Biomanufacturing momentum:
- Q2 2025 sales reached NOK 18.1 million, up 52% year-over-year (Q2 2024: NOK 11.9 million) and 33% quarter-over-quarter (Q1 2025: NOK 13.6 million). H1 2025 Biomanufacturing revenues totalled NOK 31.4 million, a 32% increase over H1 2024 (NOK 23.6 million), marking the strongest first-half performance since 2022.
- Growth was driven by increased adoption of M-SAN HQ, continued onboarding of new customers, and early integration into CDMO production workflows - all reflecting strong execution of AZT’s customer-centric strategy.
- M-SAN HQ GMP launched:
- Unlocking future high-value opportunities in gene therapy and viral vector production
- First commercial orders shipped to customers
- Product mix:
- M-SAN HQ became the Company’s top-selling product with a 62% increase over the previous highest quarter and 130% growth over last year
- CDMO traction:
- AZT recognized initial revenues from a CDMO partner integrating M-SAN into its production protocol
- Molecular Tools:
- Revenues declined 42% year-over-year and 11% sequentially, reflecting the temporary absence of orders from a key customer.
- Encouragingly, this customer placed new purchase orders totalling nearly NOK 16 million from Q3 and onwards, with deliveries and revenue recognition scheduled across the next three quarters supporting a recovery in the second half of the year.
CEO Commentary
“Q2 marked continued execution of our customer-centric strategy — one rooted in partnership, providing solutions, and supporting our customers in achieving their goals,” said Michael Akoh, CEO of ArcticZymes Technologies. “In Biomanufacturing, we’re seeing growing adoption as more customers integrate our Salt Active Nucleases into their workflows. The successful launch of GMP-grade M-SAN HQ is a clear example of how we’re responding to customer needs — providing a product they can rely on from early research through to the commercialization of their therapies. It has already unlocked new opportunities and is helping deepen our role as a long-term partner.
“In Molecular Tools, while one key customer paused orders earlier in the year, we’re encouraged by their renewed commitment, including NOK 16 million in new orders to be executed in the coming quarters, as well as growth from other accounts. These results reflect not just strong execution, but real progress in becoming a trusted partner to our customers - and in building a business positioned for sustainable, long-term value creation for shareholders,” said Michael Akoh, CEO of ArcticZymes Technologies.
Outlook
For the second half of 2025, ArcticZymes anticipates:
- Continued momentum in Biomanufacturing
- Further adoption of GMP-grade M-SAN HQ and SAN HQ neo GMP
- Expanded engagement with platform CDMOs expected to start showing real momentum in 2026 and onwards
- Recovery in Molecular Tools revenues supported by a robust order backlog
With a healthy cash position, no debt, and a growing commercial pipeline, the Company remains focused on commercial execution, operational discipline, strategic innovation, and delivering sustainable, profitable growth.
The access the report click here.
To access the Q2 presentation click here.
To access the Q2 webcast click here.
